Your browser doesn't support javascript.
loading
Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment.
Yamaji, Takayuki; Harada, Takahiro; Kajikawa, Masato; Maruhashi, Tatsuya; Kishimoto, Shinji; Yusoff, Farina Mohamad; Chayama, Kazuaki; Goto, Chikara; Nakashima, Ayumu; Tomiyama, Hirofumi; Takase, Bonpei; Kohro, Takahide; Suzuki, Toru; Ishizu, Tomoko; Ueda, Shinichiro; Yamazaki, Tsutomu; Furumoto, Tomoo; Kario, Kazuomi; Inoue, Teruo; Watanabe, Kentaro; Takemoto, Yasuhiko; Hano, Takuzo; Sata, Masataka; Ishibashi, Yutaka; Node, Koichi; Maemura, Koji; Ohya, Yusuke; Furukawa, Taiji; Ito, Hiroshi; Yamashina, Akira; Koba, Shinji; Higashi, Yukihito.
  • Yamaji T; Department of Cardiovascular Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Harada T; Department of Cardiovascular Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Kajikawa M; Division of Regeneration and Medicine, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.
  • Maruhashi T; Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Kishimoto S; Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Yusoff FM; Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Chayama K; Department of Gastroenterology and Metabolism, Institute of Biomedical and Health Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Goto C; Department of Physical Therapy, Hiroshima International University, Hiroshima, Japan.
  • Nakashima A; Division of Regeneration and Medicine, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.
  • Tomiyama H; Department of Cardiology, Tokyo Medical University, Tokyo, Japan.
  • Takase B; Division of Biomedical Engineering, National Defense Medical College Research Institute, Tokorozawa, Japan.
  • Kohro T; Department of Clinical Informatics, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Suzuki T; Cardiovascular Medicine, University of Leicester, Leicester, UK.
  • Ishizu T; Cardiovascular Division, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan.
  • Ueda S; Department of Clinical Pharmacology and Therapeutics, University of the Ryukyu School of Medicine, Okinawa, Japan.
  • Yamazaki T; Department of Clinical Epidemiology and Systems, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
  • Furumoto T; Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
  • Kario K; Division of Cardiovascular Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Inoue T; Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan.
  • Watanabe K; Department of Neurology, Hematology, Metabolism, Endocrinology and Diabetelogy (DNHMED), Yamagata University School of Medicine, Yamagata, Japan.
  • Takemoto Y; Department of Internal Medicine and Cardiology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Hano T; Department of Medical Education and Population-based Medicine, Postgraduate School of Medicine, Wakayama Medical University, Wakayama, Japan.
  • Sata M; Department of Cardiovascular Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.
  • Ishibashi Y; Department of General Medicine, Shimane University Faculty of Medicine, Izumo, Japan.
  • Node K; Department of Cardiovascular and Renal Medicine, Saga University, Saga, Japan.
  • Maemura K; Department of Cardiovascular Medicine, Course of Medical and Dental Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
  • Ohya Y; The Third Department of Internal Medicine, University of the Ryukyus, Okinawa, Japan.
  • Furukawa T; Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Ito H; Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
  • Yamashina A; Department of Cardiology, Tokyo Medical University, Tokyo, Japan.
  • Koba S; Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan.
  • Higashi Y; Division of Regeneration and Medicine, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.
J Atheroscler Thromb ; 31(4): 478-500, 2024 Apr 01.
Article en En | MEDLINE | ID: mdl-37926523
ABSTRACT

AIM:

There is little information on the relationships of serum small dense low-density lipoprotein cholesterol (sdLDL-C) levels and serum triglyceride (TG) levels with cardiovascular events in patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM) who are receiving statins. The aim of this study was to evaluate the relationships of serum TG levels and sdLDL-C levels as residual risks for cardiovascular events in patients with CAD and type 2 DM who were being treated with statins.

METHODS:

The subjects were divided into four groups based on TG levels and sdLDL-C levels sdLDL-C of ＜40.0 mg/dL and TG of ＜150 mg/dL, sdLDL-C of ≥ 40.0 mg/dL and TG of ＜150 mg/dL, sdLDL-C of ＜40.0 mg/dL and TG of ≥ 150 mg/dL, and sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL. During a median follow-up period of 1419 days, cardiovascular events occurred in 34 patients.

RESULTS:

The incidences of cardiovascular events were significantly higher in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of ＜150 mg/dL and in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL, but not in patients with sdLDL-C of ＜40.0 mg/dL and TG of ≥ 150 mg/dL, than in patients with sdLDL-C of ＜40.0 mg/dL and TG of ＜150 mg/dL.

CONCLUSIONS:

Under the condition of treatment with statins, patients with CAD and type 2 DM who had sdLDL-C levels of ≥ 40.0 mg/dL had a high risk for cardiovascular events even though serum TG levels were controlled at ＜150 mg/dL.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de la Arteria Coronaria / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Diabetes Mellitus Tipo 2 Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de la Arteria Coronaria / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Diabetes Mellitus Tipo 2 Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article